BMC Pharmacology and Toxicology, Journal Year: 2025, Volume and Issue: 26(1)
Published: Jan. 29, 2025
Language: Английский
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: May 20, 2024
Abstract Tumor biomarkers, the substances which are produced by tumors or body’s responses to during tumorigenesis and progression, have been demonstrated possess critical encouraging value in screening early diagnosis, prognosis prediction, recurrence detection, therapeutic efficacy monitoring of cancers. Over past decades, continuous progress has made exploring discovering novel, sensitive, specific, accurate tumor significantly promoted personalized medicine improved outcomes cancer patients, especially advances molecular biology technologies developed for detection biomarkers. Herein, we summarize discovery development including history conventional innovative used biomarker classification biomarkers based on tissue origins, application clinical management. In particular, highlight recent advancements biomarker-based anticancer-targeted therapies emerging as breakthroughs promising strategies. We also discuss limitations challenges that need be addressed provide insights perspectives turn into opportunities this field. Collectively, multiple emphasized review may guidance precision medicine, broaden horizons future research directions, expedite patients according their rather than organs origin.
Language: Английский
Citations
148
Cell, Journal Year: 2023, Volume and Issue: 186(12), P. 2628 - 2643.e21
Published: June 1, 2023
Language: Английский
Citations
72
Nature reviews. Cancer, Journal Year: 2023, Volume and Issue: 23(10), P. 673 - 685
Published: July 27, 2023
Language: Английский
Citations
62
Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14
Published: April 21, 2023
As traditional strategies for cancer treatment, some chemotherapy agents, such as doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, and paclitaxel exert their anti-tumor effects by inducing immunogenic cell death (ICD) of tumor cells. ICD induces immunity through release of, or exposure to, damage-related molecular patterns (DAMPs), including high mobility group box 1 (HMGB1), calreticulin, adenosine triphosphate, heat shock proteins. This leads to activation tumor-specific immune responses, which can act in combination with the direct killing functions drugs on cells further improve curative effects. In this review, we highlight mechanisms underlying ICD, those several chemotherapeutic DAMPs exposed during activate system, well discussing prospects application potential role immunotherapy, aim providing valuable inspiration future development chemoimmunotherapy.
Language: Английский
Citations
58
Molecular Cell, Journal Year: 2023, Volume and Issue: 83(22), P. 4062 - 4077.e5
Published: Nov. 1, 2023
Abnormal increases in cell size are associated with senescence and cycle exit. The mechanisms by which overgrowth primes cells to withdraw from the remain unknown. We address this question using CDK4/6 inhibitors, arrest G0/G1 licensed treat advanced HR+/HER2- breast cancer. demonstrate that CDK4/6-inhibited overgrow during G0/G1, causing p38/p53/p21-dependent withdrawal. Cell withdrawal is triggered biphasic p21 induction. first wave caused osmotic stress, leading p38- size-dependent accumulation of p21. inhibitor washout results some entering S-phase. Overgrown experience replication resulting a second promotes G2 or subsequent G1. propose levels integrate signals overgrowth-triggered stresses determine fate. This model explains how hypertrophy can drive why inhibitors have long-lasting effects patients.
Language: Английский
Citations
44
Cancer Gene Therapy, Journal Year: 2024, Volume and Issue: 31(9), P. 1283 - 1291
Published: Feb. 26, 2024
Dysregulated cellular proliferation represents a hallmark feature across all cancers. Aberrant activation of the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway, independent mitogenic signaling, engenders uncontrolled breast cancer cell proliferation. Consequently, advent CDK4/6 inhibition has constituted pivotal milestone in realm targeted therapy. The combination inhibitors (CDK4/6i) with endocrine therapy (ET) emerged as foremost therapeutic modality for patients afflicted hormone receptor-positive (HR + )/HER2-negative (HER2-) advanced cancer. At present, Food Drug Administration (FDA) sanctioned various CDK4/6i employment primary treatment regimen HR /HER2- This approach demonstrated substantial extension progression-free survival (PFS), often amounting to several months, when administered alongside Within this comprehensive review, we systematically evaluate utilization strategies subpopulations explore potential avenues following disease progression during application
Language: Английский
Citations
42
Therapeutic Advances in Medical Oncology, Journal Year: 2024, Volume and Issue: 16
Published: Jan. 1, 2024
Epigenetic alterations, including aberrant DNA methylation, are now recognized as bone fide hallmarks of cancer, which can contribute to cancer initiation, progression, therapy responses and resistance. Methylation gene promoters have a range impacts on risk, clinical stratification therapeutic outcomes. We provide several important examples genes, be silenced or activated by promoter methylation highlight their implications. These include the mismatch repair genes MLH1 MSH2, homologous recombination BRCA1 RAD51C, TERT oncogene within P15/P16/RB1/E2F tumour suppressor axis. also discuss how these changes might occur in first place – whether context CpG island methylator phenotype constitutional methylation. The choice assay used measure significant impact interpretation states, some where this influence decision-making presented. Aberrant patterns circulating (ctDNA) showing great promise non-invasive detection monitoring using liquid biopsies; however, caution must taken interpreting results cases may present. Thus, review aims researchers clinicians with comprehensive summary broad, but subject, illustrating potentials pitfalls assessing cancer.
Language: Английский
Citations
20
Nature Reviews Urology, Journal Year: 2024, Volume and Issue: 21(11), P. 662 - 675
Published: May 2, 2024
Language: Английский
Citations
20
Nature, Journal Year: 2024, Volume and Issue: 630(8015), P. 214 - 221
Published: May 29, 2024
Language: Английский
Citations
19
Nature Cancer, Journal Year: 2024, Volume and Issue: 5(7), P. 996 - 1009
Published: March 5, 2024
Abstract Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have revolutionized breast cancer therapy. However, <50% of patients an objective response, nearly all develop resistance during To elucidate the underlying mechanisms, we constructed interpretable deep learning model response to palbociclib, a CDK4/6i, based on reference map multiprotein assemblies in cancer. The identifies eight core that integrate rare common alterations across 90 genes stratify palbociclib-sensitive versus palbociclib-resistant cell lines. Predictions translate patient-derived xenografts, whereas single-gene biomarkers do not. Most predictive can be shown by CRISPR–Cas9 genetic disruption regulate CDK4/6i response. Validated relate cell-cycle control, growth factor signaling histone regulatory complex show promotes S-phase entry through activation modifiers KAT6A TBL1XR1 transcription RUNX1. This study enables integrated assessment how tumor’s profile modulates resistance.
Language: Английский
Citations
18